Stocks of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) traded higher last session on Wall Street, up 1.59% to $57.67.
CRNX stock price is now 3.77% away from the 50-day moving average and 17.02% away from the 200-day moving average. The market capitalization of the company currently stands at $5.35B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $68, Citigroup recently initiated with Buy rating for Crinetics Pharmaceuticals Inc (NASDAQ: CRNX). On January 16, 2024, Morgan Stanley recently initiated its ‘Overweight’ rating on the stock quoting a target price of $50, while ‘Jefferies’ rates the stock as ‘Hold’
In other news, Knight Jeff E., Chief Operating Officer sold 501 shares of the company’s stock on Nov 22 ’24. The stock was sold for $28,317 at an average price of $56.52. Upon completion of the transaction, the Chief Operating Officer now directly owns 51,653 shares in the company, valued at $2.98 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 03 ’24, Chief Med and Dev Officer Pizzuti Dana sold 14,375 shares of the business’s stock. A total of $785,306 was realized by selling the stock at an average price of $54.63. This leaves the insider owning 28,507 shares of the company worth $1.64 million. A total of 6.51% of the company’s stock is owned by insiders.
During the past 12 months, Crinetics Pharmaceuticals Inc has had a low of $30.87 and a high of $62.53. As of last week, the company has a debt-to-equity ratio of 0.06, a current ratio of 16.38, and a quick ratio of 16.38. The fifty day moving average price for CRNX is $55.4784 and a two-hundred day moving average price translates $49.1737 for the stock.
The latest earnings results from Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) was released for 2024-09-30.
